In human patients with epidermal growth factor receptor 2 (HER2)-overexpressing gastric cancer, combination treatment with trastuzumab, anti-HER2 antibody, and chemotherapy with cisplatin and fluoropyrimidine-based regimens resulted in longer overall survival than chemotherapy alone [4]. This evidence concerns the gene ERBB2 and gastric cancer.